{"name":"Beijing Mabworks Biotech Co., Ltd.","slug":"beijing-mabworks-biotech-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MIL62","genericName":"MIL62","slug":"mil62","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"lenalinomide","genericName":"lenalinomide","slug":"lenalinomide","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"mil60","genericName":"mil60","slug":"mil60","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"MIL62","genericName":"MIL62","slug":"mil62","phase":"phase_3","mechanism":"MIL62 is a monoclonal antibody targeting IL-6 receptor to inhibit interleukin-6 signaling and reduce inflammatory responses.","indications":["Rheumatoid arthritis","Other IL-6-driven inflammatory conditions"],"catalyst":""},{"name":"lenalinomide","genericName":"lenalinomide","slug":"lenalinomide","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"mil60","genericName":"mil60","slug":"mil60","phase":"phase_3","mechanism":"mil60 is a monoclonal antibody targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQczFaMW1rekJaNmo3bVNnMEJQUmJkSWxPa0tQYmt0T2I3TW5CY1F3VmQ0eWpKcjZDOWVpMnNFQjFkd01ZSkQwRTI4TDRjTF9KMS1VRFNoODBObDE3elJaVTVZN1lvRmMtVl9COU1LX3dZRFlCSkdfcDYxVzNza1dWSU1ZbUoyUlRyZUt6TVZLVTRHYjhhYnozNG91TzhpTUxoVVhUNjlER0huVGFSV3ctb2gtMWE1NU4wSEhBWkJLbkk1amtmbFhVS09UcVF6QXNQR1dFQmczRDhZZENrUVJRVlVPVDNLaDVqZkJ3R2Vvbi1EYjk2R1dyVU1VQkctaTBKM0EycmZPNXVRQnJ3OWpzVFRrUW0wVWxFdWdqLUhhUUtyV0lsSUdHVmh4MS1XMUJTLS02SzJUWl8xdmYwSDE4?oc=5","date":"2026-04-01","type":"regulatory","source":"GlobeNewswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline - GlobeNewswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQWGxYVGFLMVdLcTNEQkFrYmJOdmVVQ3BGcDlxNWRxZi1Pczl4SnJrdUxBdzFvaVY2UUVaUEZpbmMweTlFTFp4cDRlTmMyN3FrcDI5b3phUlJLMndKOXE5Z3FrOU5ZZlJvVkFXV3dhYWhGbGhhTHZCWEQ4SWRZcUU5Sm1HUWtWQ1MwZVFCWnBSZEV0R1dCUXBR?oc=5","date":"2026-03-23","type":"regulatory","source":"openPR.com","summary":"Marginal Zone Lymphoma Pipeline 2026: FDA Updates, Therapy - openPR.com","headline":"Marginal Zone Lymphoma Pipeline 2026: FDA Updates, Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOcnpGaFhkeDJzWENZQzR3dVhmWVFKb0tmZlhwZDhiSTd4RVZnTGxJeEFsZDVUY3QtSUJpdkk1aTZrY0Z0MTBoZ0pwUzlyeE9JYmV6djltX1RGeUJVMWtfTkxsQndNcEJxaDlWS3d6a1BMOU5jdHJpVnpzVzJ6UWE2blpndjlsMTR6QW5aTzRwS2xXNmxCcnc?oc=5","date":"2025-11-26","type":"regulatory","source":"BioWorld News","summary":"Otsuka’s IgAN therapy gets a thumbs-up from the FDA - BioWorld News","headline":"Otsuka’s IgAN therapy gets a thumbs-up from the FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOdF8yTXJlNGFhOHdaMGItM3pkRVVxSDJ1XzlUcHFEamVvSXI0dlZHTjB1ZXQwZHM1Y21sVDlJTEt2a3NEQUo5RV95TTctYUtXcDlVNDFabDVMa3F3UFRwU0RRRFl2cTdyc1Z4S3VSeFJyY2pMZWQ1akxaU3dBeS1ETUJuQmlrS2hRSVRldFRLOUdaUUY0dlE3R2I3Uk9HczZEZDFtZXJhVQ?oc=5","date":"2025-11-18","type":"regulatory","source":"BioWorld News","summary":"Henlius, Organon win US FDA approval of first Perjeta biosimilar - BioWorld News","headline":"Henlius, Organon win US FDA approval of first Perjeta biosimilar","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQRzl6R0F6T2dkNFJQdFZUN2ZIUFZVVEFkemRVSmhIcDZlbFA0TXZMTjlQQ0ROUnNDRGVfOTRTdXlYYXFRdUlWa01sX1JJaFJtT09QRE5HcjhMU0FfS2lkYTVneTVINWNIZWVOZ2ZNd3ptMzl1d2Z4ampfZ21WME5KQ0lYemhXQ0R5eXVQR3l1NVlsVXBET0pEcnRpV0g?oc=5","date":"2025-01-14","type":"trial","source":"Oncology Pipeline","summary":"AbbVie takes a tentative step into bispecific T-cell engagers | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"AbbVie takes a tentative step into bispecific T-cell engagers | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9JZkpkbGp2VjktbWNYWjFmam9LQUJiTDNhcGN1NmJNU0VBUm5MMXBIYTdVWWpqRW1BU3pjOU9FNnBtSUVZLV9vVG1DbDNXMHlTOWU0bkhFYTlfb2VqbUktVWU5R2cxcklPX3gyUmZLN3hDRXVzc08xNU1iWnluczQ?oc=5","date":"2025-01-10","type":"deal","source":"Pharmaceutical Technology","summary":"Climb Bio enters licensing deal with Mabworks for CLYM116 development - Pharmaceutical Technology","headline":"Climb Bio enters licensing deal with Mabworks for CLYM116 development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"prnewswire.com","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - prnewswire.com","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPeEdVMzUwTHhqSEJ4OE9PTjNTM3cxNzdPcjdUYlROZEd5dVg5VTBxdGMyUzdDYjR6UEhsOWpzVTFSaVBBQTVwN21qR1Z0dUVoSW9xMFppWkxCYlByQVZLanJGZ2RkMGw1S1dzSG9Udm1nX3VjMDJCZElyX20zV2R1MXpKOEdvbndKSTJ0U3RFcjkyem10b2Vnd0hyT05qb3hJM1c0WjQzdGhjVC1kU3NRcDQ1Y09XcnZvbU93a3ZoaVdqTjItTFFOUUw4Tnc0NnZjcmw4WUxMWlF2NnlPM3AtYTItNUhHUjFsU1dtTTVMVXFocVVpd0phZlBWbWFfdw?oc=5","date":"2020-06-22","type":"deal","source":"prnewswire.com","summary":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China - prnewswire.com","headline":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}